

Optimal Frequency of Visits for Patients with Systemic Lupus Erythematosus to Measure Disease Activity Over Time

DOMINIQUE IBAÑEZ, DAFNA D. GLADMAN, ZAHİ TOUMA, MANDANA NIKPOUR, and MURRAY B. UROWITZ

ABSTRACT. Objective. Adjusted mean Systemic Lupus Erythematosus Disease Activity Index (SLEDAI; AMS) measures lupus disease activity over time. Our aim was to determine optimal visit frequency for calculating AMS.

Methods. Patients followed monthly for 12 consecutive visits were included. AMS was calculated using all of the SLEDAI 2000 (AMS_{GOLD} using all 12 visits), only quarterly visits (AMS₃, using visits 3 months apart), semiannual visits (AMS₆, using first, middle, and last visits only), and annual visits (AMS₁₂, using only the first and last visits). Comparisons of AMS₃, AMS₆, and AMS₁₂ with AMS_{GOLD} are made using descriptive statistics.

Results. Seventy-eight patients were included (92% women, mean age at SLE diagnosis 30.1 yrs and at study start 46.2 yrs). The mean (SD) AMS_{GOLD} for the entire year was 2.05 (1.66), for AMS₃ 1.99 (1.65), for AMS₆ 2.12 (1.87), and for AMS₁₂ 2.08 (1.83). Mean (SD) of the absolute differences with AMS_{GOLD}: for AMS₃ 0.29 (0.33), for AMS₆ 0.45 (0.59), and for AMS₁₂ 0.61 (0.58). Differences that were < 0.5 were considered minimal while those ≥ 1 were deemed important. Comparing AMS_{GOLD} to AMS₃, 82% of the differences were minimal and 3% were important. When comparing to AMS₆, 68% were minimal and 10% were important, while comparing to AMS₁₂, 50% were minimal and 21% were important.

Conclusion. Usual clinic visits occurring quarterly offer a good estimation of disease activity over a 1-year period and are preferred over semiannual and annual visits. (First Release Nov 15 2010; J Rheumatol 2011;38:60–3; doi:10.3899/jrheum.100575)

Key Indexing Terms:

SYSTEMIC LUPUS ERYTHEMATOSUS
ADJUSTED MEAN SLEDAI

DISEASE ACTIVITY
LONGITUDINAL STUDY

Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown cause. It affects primarily women in their childbearing years and has a variable course and prognosis. The disease may affect any organ system in the body, and because of the protean manifestations it has been difficult to assess disease activity. Several instruments to measure disease activity have been developed. Among the most commonly used are the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), first developed in 1985¹, and last modified in 2000 (SLEDAI-2K)²; the British Isles Lupus

Activity Group (BILAG), first developed in 1988³ and last modified in 2004⁴; and the Systemic Lupus Activity Measure (SLAM)⁵ and its modification SLAM-R⁶. These measures have been proven comparable in individual visits, and have demonstrated sensitivity to change over time.

SLEDAI has been validated as a tool to assess disease activity in SLE. It has demonstrated reproducibility when both experienced lupologists and novices assess patients^{7,8}. It has also shown sensitivity to change⁹. High SLEDAI scores predict outcomes in SLE including death and damage accumulation. SLEDAI-2K is identical to the original SLEDAI except for the definition of 4 items: alopecia, mucous membrane ulcers, rash, and proteinuria, which are recorded if there is persistent inflammation, while in the original SLEDAI would be recorded only if they were new. Its validity has been shown against the original SLEDAI². While the SLEDAI was initially developed to measure disease activity in the preceding 10 days, it has now been shown to be valid to measure disease activity in the preceding 30 days¹⁰.

SLEDAI-2K assesses disease activity at a particular visit. To describe disease activity over time, the adjusted mean SLEDAI-2K (AMS) was developed. The AMS calculates

From the University of Toronto Lupus Clinic and Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada; and the University of Melbourne, Department of Medicine, St. Vincent's Hospital, Melbourne, Victoria, Australia.

D. Ibañez, MSc; D.D. Gladman, MD, FRCPC; Z. Touma, MD; M.B. Urowitz, MD, FRCPC, University of Toronto Lupus Clinic and Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto Western Hospital; M. Nikpour, MD, FACP, University of Melbourne, Department of Medicine, St. Vincent's Hospital.

Address correspondence to Dr. D.D. Gladman, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, 1E-410B, 399 Bathurst Street, Toronto, Ontario M5T 2S8, Canada.

E-mail: dafna.gladman@utoronto.ca

Accepted for publication September 21, 2010.

the area under the curve of SLEDAI-2K divided by the length of the time interval¹¹. The AMS has been shown to reflect burden of disease and is an important prognostic marker¹².

In drug trials, patients are usually followed at monthly intervals. Consecutive monthly assessments measure the entire disease activity in the time interval. However, in clinical practice and longitudinal observational cohort studies, patients are seen at 3-monthly intervals, and at times miss their appointments and are then followed at irregular intervals. It is therefore important to know whether the assessment of disease activity over time as measured by the AMS can be applied to patients followed at intermittent intervals. Our aims were (1) to compare AMS obtained over a 1-year period when visits are done monthly to AMS obtained using quarterly, semiannual, or annual visits; and (2) to determine the optimal frequency of visits to measure disease activity. Both aims are assessed in individual patients and in patient cohorts.

MATERIALS AND METHODS

Patient selection. Patients registered at the University of Toronto Lupus Clinic who were seen monthly by the same experienced physician for a 12-month period were included. Clinical and laboratory information was collected according to a standard protocol, which includes a detailed clinical history, physical examination, and laboratory evaluation.

Assessment of disease activity. The SLEDAI-2K was calculated at each monthly visit. Several calculations of the AMS were performed. AMS_{GOLD} was considered the “gold standard” for our study and was based on the AMS calculated using all of the monthly visits. AMS₃ was defined as the AMS calculated using visits that are 3 months apart (quarterly visits). AMS₆ was defined based on the AMS calculated using visits that are 6 months apart (semiannual visits). AMS₁₂ was defined as the AMS calculated using the first and last visits (annual visits). Flare was defined as an increase in SLEDAI-2K of 4 or more between 2 consecutive monthly visits².

Statistical analysis. Descriptive statistics included t tests and plots to represent distribution of AMS_{GOLD}, AMS₃, AMS₆, and AMS₁₂ in the group as a whole and in individual patients.

The difference in estimating AMS was calculated based on the absolute

difference between AMS_{GOLD} and AMS₃, AMS₆, and AMS₁₂. This is called the “error” associated with visit frequency.

Presence of flare was determined in each patient using monthly visits. AMS_{GOLD} was compared among patients with and without flares. The magnitude of this difference was labeled an “important error.”

RESULTS

Patient characteristics. Seventy-eight patients with SLE were seen monthly for 12 consecutive visits. Seventy-two (92%) were women and 6 (8%) were men, with a mean (\pm SD) age at SLE diagnosis of 30.7 ± 11.4 years; mean age at start of study of 46.2 ± 12.0 years; and mean disease duration of 15.5 ± 9.7 years. The mean SLEDAI-2K at each of the monthly visits is provided in Table 1. In total, 25 (32%) of the patients had at least 1 visit with a SLEDAI-2K score > 4 .

Assessment of disease activity. Table 2 and Figure 1 depict the distribution of AMS using monthly, quarterly, semiannual, and annual visits for the whole group. For the whole group there is no statistically significant difference in the estimation of AMS regardless of the time interval used for its calculation. For the group as a whole, mean AMS obtained through quarterly, semiannual, or annual visits all perform quite well, all within 0.07 from mean AMS_{GOLD}.

Determination of error. Table 3 provides the distribution of errors between AMS_{GOLD} and AMS₃, AMS₆, and AMS₁₂ for individual patients, and indicates a dose-response relationship. The more frequent the visits, the better the estimate of the AMS_{GOLD}. Figure 2 provides the distribution per patient in addition to the magnitude of the error.

Determination of important error. Based on the SLEDAI-2K definition of flare of an increase of 4 or more, and using the monthly visits, 25 patients had at least 1 flare during the study period, while 53 patients did not have a flare. A comparison of AMS_{GOLD} among patients with flares (2.74 ± 1.44) or without flare (1.72 ± 1.67) revealed a statistically significant difference of magnitude 1.0 ($p = 0.01$).

Table 1. Mean Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) at each of the monthly visits.

Visit	SLEDAI-2K, mean \pm SD	Minimum, Maximum	Median	No. Patients with SLEDAI-2K > 4 (%)
1	2.21 \pm 2.34	0, 10	2.00	10 (12.8)
2	2.40 \pm 2.35	0, 8	2.00	13 (16.7)
3	2.28 \pm 2.65	0, 15	2.00	15 (19.2)
4	2.15 \pm 1.96	0, 8	2.00	8 (10.3)
5	2.23 \pm 2.19	0, 12	2.00	8 (10.3)
6	2.18 \pm 2.16	0, 10	2.00	7 (9.0)
7	1.86 \pm 1.93	0, 10	2.00	3 (3.8)
8	1.90 \pm 1.89	0, 10	2.00	4 (5.1)
9	1.83 \pm 1.79	0, 6	2.00	5 (6.4)
10	1.82 \pm 1.90	0, 8	2.00	6 (7.7)
11	1.84 \pm 1.80	0, 8	2.00	5 (6.4)
12	1.93 \pm 1.78	0, 6	2.00	3 (3.8)

Table 2. Distribution of adjusted mean Systemic Lupus Erythematosus Disease Activity Index (AMS) using monthly, quarterly, semiannual, and annual visits for the whole group.

Visit Frequency	Mean \pm SD	Minimum, Maximum	Median	p*
Monthly: AMS _{GOLD}	2.05 \pm 1.66	0, 6.43	2.00	
Quarterly: AMS ₃	1.99 \pm 1.65	0, 6.99	1.90	0.83
Semiannual: AMS ₆	2.12 \pm 1.87	0, 8.00	2.00	0.79
Annual: AMS ₁₂	2.08 \pm 1.83	0, 6.00	2.00	0.92

* t test compared to AMS_{GOLD}.




Figure 1. Distribution of adjusted mean Systemic Lupus Erythematosus Disease Activity Index using monthly, quarterly, semiannual, and annual visits, for the whole group.

Based on this difference, an important error was defined as a difference of 1. Evaluating the percentage of patients with an important error when using the different visit frequencies, we see that for AMS₃ it occurred in 3% of patients, for AMS₆ in 10%, and for AMS₁₂, 21%.

DISCUSSION

The assessment of disease activity is important in evaluating patients with SLE. This is relevant in clinical practice and in longitudinal observational cohort studies, as well as in clinical trials of new medications. In randomized clinical trials, patients are typically assessed at monthly intervals. The American College of Rheumatology Ad Hoc Committee on SLE Guidelines for referral and management of SLE in adults recommended that the frequency of visits in patients

with SLE be at least every 3 months¹³. However, in clinical practice and longitudinal observational cohort studies, patients often miss visits and may be seen semiannually or even annually instead.

We have previously described a method for calculating disease activity over time for patients seen on a regular basis¹¹. The frequency of visits, however, may have an effect on the accurate determination of disease activity over time. Therefore, we sought to determine whether the frequency of visits would affect the accuracy of estimating the AMS in patients with SLE. We demonstrate that when groups of patients are analyzed, the frequency of visits within 1 year does not have a significant effect on the mean AMS. The difference between the AMS_{GOLD} and the AMS₃, AMS₆, and AMS₁₂ was within 0.07, a difference that is neither clinically nor statistically significant. Thus, when comparing groups of patients, yearly visits may suffice to describe disease activity over time.

At the patient level, there are errors in the estimation of AMS depending on the visit frequency. Indeed, there is an increasingly larger error with less frequent visits, such that when a patient is seen at 12-month intervals, the average error increases to 0.61 when compared to the monthly interval visits.

Patients who flared during the year of followup had an AMS_{GOLD} with a magnitude of 1 greater than patients who did not flare. This is defined as an important error. Based on this definition, there was an increasing percentage of important error based on the frequency of visits, with low occurrence of $\leq 10\%$ noted for visits of ≤ 6 months and 21% for yearly visits. Thus in therapeutic trials, when disease activity over time is used as an outcome, landmark analyses at the end of the trial, usually at 1 year, may not accurately

Table 3. Distribution of errors between AMS_{GOLD} and AMS₃, AMS₆, and AMS₁₂ for individual patients.

Error Between AMS _{GOLD} and	Mean \pm SD	Minimum, Maximum	Median	95% CI	p*
Quarterly: AMS ₃	0.29 \pm 0.33	0, 1.75	0.18	0.21, 0.36	< 0.0001
Semiannual: AMS ₆	0.45 \pm 0.59	0, 3.76	0.28	0.32, 0.58	< 0.0001
Annual: AMS ₁₂	0.61 \pm 0.58	0, 2.48	0.47	0.48, 0.74	< 0.0001

* Paired t test. AMS: Adjusted mean Systemic Lupus Erythematosus Disease Activity Index.




Figure 2. Distribution of errors by visit frequency.

describe total disease activity during the followup. This study shows that visits up to 3 months apart provide a good estimation of disease activity over time. Visits beyond 3 months compromise this measure.

A strength of our study is that all patients were evaluated by the same experienced physician, with data gathered in a uniform way and described with the same activity index.

The study patients selected were not different from the rest of the patients seen in the clinic in terms of sex, age at SLE diagnosis, or disease duration, but had a lower average SLEDAI-2K value [4.21 ± 4.54 for the clinic patients compared to 2.06 ± 2.19 for the study group ($p < 0.0001$)]. A potential weakness lies in the fact that overall, the disease activity in these patients was low, with only 25 patients with a SLEDAI-2K > 4 . Whether the same results would be true for patients with higher SLEDAI-2K scores remains to be determined.

When assessing groups of patients, visit frequency of every 3, 6, or 12 months does not affect the mean AMS. In individual patients, usual clinical visits occurring quarterly offer a good estimation of disease activity over a 1-year period and are preferred over semiannual and annual visits.

REFERENCES

- Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and The Committee on Prognosis Studies in SLE. The development and validation of the SLE Disease Activity Index (SLEDAI). *Arthritis Rheum* 1992;35:630-40.
- Gladman DD, Ibañez D, Urowitz MB. SLE Disease Activity Index 2000. *J Rheumatol* 2002;29:288-91.
- Symmons DP, Coppock JS, Bacon PA, Bresnihan B, Isenberg DA, Maddison P, et al. Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). *Q J Med* 1988;69:927-37.
- Isenberg DA, Rahman A, Allen E, Farewell V, Akil M, Bruce IN, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. *Rheumatology* 2005;44:902-6.
- Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. *Arthritis Rheum* 1989;32:1107-18.
- Bae SC, Koh HK, Chang DK, Kim MH, Park JK, Kim SY. Reliability and validity of systemic lupus activity measure-revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus. *Lupus* 2001;10:405-9.
- Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Bombardier C, Chang CH, et al. Cross-cultural validation of three disease activity indices in systemic lupus erythematosus (SLE). *J Rheumatol* 1992;19:608-11.
- Hawker G, Gabriel S, Bombardier C, Goldsmith C, Caron D, Gladman DD. A reliability study of SLEDAI: A disease activity index for systemic lupus erythematosus (SLE). *J Rheumatol* 1993;20:657-60.
- Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Bombardier C, Isenberg DA, et al. Sensitivity to change of 3 systemic lupus erythematosus disease activity indices: international validation. *J Rheumatol* 1994;21:1468-71.
- Touma Z, Urowitz MB, Gladman DD. SLEDAI-2K for a 30-day window. *Lupus* 2010;19:49-51.
- Ibañez D, Urowitz MB, Gladman DD. Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus. *J Rheumatol* 2003;30:1977-82.
- Ibañez D, Urowitz MB, Gladman DD. Disease activity over time (adjusted mean SLEDAI) predicts mortality and damage in SLE. *J Rheumatol* 2005;32:824-7.
- Gladman DD, Urowitz MB, Esdaile JM, Hahn BH, Klippel J, Lahita R, et al. American College of Rheumatology Ad Hoc Committee on SLE Guidelines. Guidelines for referral and management of systemic lupus erythematosus in adults. *Arthritis Rheum* 1999;42:1785-96.